A no for oral cladribine in Europe

A

The European Medicines Agency confirmed its previous negative opinion and adopted a final negative opinion, recommending that oral cladribine, from Serono Europe Ltd, should not be granted a marketing authorisation. Oral cladribine was intended as disease-modifying therapy in relapsing remitting multiple sclerosis.

Click here for EMA statement

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

Add comment

By Prof G

Translate

Categories

Recent Posts

Recent Comments

Archives